Cargando…

Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis

PURPOSE: Cardiac surgery patients always present with atrial fibrillation (AF) after admission to the intensive care unit, leading to high mortality and lengthy hospitalization. Dexmedetomidine (DEX) is a popular medication used for sedation in the intensive care unit; however, whether it can reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhipeng, Zhou, Hongmei, Ni, Yunjian, Wu, Cheng, Zhang, Caijun, Ling, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856293/
https://www.ncbi.nlm.nih.gov/pubmed/29559768
http://dx.doi.org/10.2147/DDDT.S153834
_version_ 1783307279866527744
author Zhu, Zhipeng
Zhou, Hongmei
Ni, Yunjian
Wu, Cheng
Zhang, Caijun
Ling, Xiaoyan
author_facet Zhu, Zhipeng
Zhou, Hongmei
Ni, Yunjian
Wu, Cheng
Zhang, Caijun
Ling, Xiaoyan
author_sort Zhu, Zhipeng
collection PubMed
description PURPOSE: Cardiac surgery patients always present with atrial fibrillation (AF) after admission to the intensive care unit, leading to high mortality and lengthy hospitalization. Dexmedetomidine (DEX) is a popular medication used for sedation in the intensive care unit; however, whether it can reduce AF needs to be analyzed. MATERIALS AND METHODS: Three primary databases, Medline, Embase (Ovid SP) and the Cochrane Central Register of Controlled Trials (CENTRAL), were searched. All English language and randomized control designed clinical publications comparing DEX to control medicines for sedation after elective cardiac surgery were included. Two independent colleagues conducted the data extraction and quality assessments. The subgroup analysis was performed according to the medicine used, age, AF history, and whether previous beta-blocker premedication and cardiopulmonary bypass (CPB) were applied. The overall incidence of AF was analyzed. RESULTS: A total of 1,295 patients in nine studies met the selection criteria among 2,587 studies screened from the database. After quantitative synthesis, our results revealed that the DEX group was not associated with a decreased incidence of AF compared with the placebo (risk ratio [RR] 0.76, 95% CI 0.37, 1.55, P=0.44) and morphine groups (RR 0.86, 95% CI 0.56, 1.31, P=0.48). Subgroup analysis also indicated that the DEX vs propofol comparison exhibited no difference: 1) for patients of age >60 years (P=0.69) or ≤60 years (P=0.69); 2) under CPB surgery (P=0.45) or without CPB surgery (P=0.88); 3) with beta-blocker premedication (P=0.32) or without beta-blocker premedication (P=0.90); and 4) with AF history (RR 1.07, 95% CI 0.85, 1.36, P=0.57) or without AF history (P=0.30). CONCLUSION: This meta-analysis revealed that DEX could not reduce the incidence of AF compared to control medicines following cardiac surgery. DEX may have an increased influence on AF occurrence if patients had a history of AF. However, cautious interpretation should be made due to high clinical heterogeneity.
format Online
Article
Text
id pubmed-5856293
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58562932018-03-20 Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis Zhu, Zhipeng Zhou, Hongmei Ni, Yunjian Wu, Cheng Zhang, Caijun Ling, Xiaoyan Drug Des Devel Ther Review PURPOSE: Cardiac surgery patients always present with atrial fibrillation (AF) after admission to the intensive care unit, leading to high mortality and lengthy hospitalization. Dexmedetomidine (DEX) is a popular medication used for sedation in the intensive care unit; however, whether it can reduce AF needs to be analyzed. MATERIALS AND METHODS: Three primary databases, Medline, Embase (Ovid SP) and the Cochrane Central Register of Controlled Trials (CENTRAL), were searched. All English language and randomized control designed clinical publications comparing DEX to control medicines for sedation after elective cardiac surgery were included. Two independent colleagues conducted the data extraction and quality assessments. The subgroup analysis was performed according to the medicine used, age, AF history, and whether previous beta-blocker premedication and cardiopulmonary bypass (CPB) were applied. The overall incidence of AF was analyzed. RESULTS: A total of 1,295 patients in nine studies met the selection criteria among 2,587 studies screened from the database. After quantitative synthesis, our results revealed that the DEX group was not associated with a decreased incidence of AF compared with the placebo (risk ratio [RR] 0.76, 95% CI 0.37, 1.55, P=0.44) and morphine groups (RR 0.86, 95% CI 0.56, 1.31, P=0.48). Subgroup analysis also indicated that the DEX vs propofol comparison exhibited no difference: 1) for patients of age >60 years (P=0.69) or ≤60 years (P=0.69); 2) under CPB surgery (P=0.45) or without CPB surgery (P=0.88); 3) with beta-blocker premedication (P=0.32) or without beta-blocker premedication (P=0.90); and 4) with AF history (RR 1.07, 95% CI 0.85, 1.36, P=0.57) or without AF history (P=0.30). CONCLUSION: This meta-analysis revealed that DEX could not reduce the incidence of AF compared to control medicines following cardiac surgery. DEX may have an increased influence on AF occurrence if patients had a history of AF. However, cautious interpretation should be made due to high clinical heterogeneity. Dove Medical Press 2018-03-12 /pmc/articles/PMC5856293/ /pubmed/29559768 http://dx.doi.org/10.2147/DDDT.S153834 Text en © 2018 Zhu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zhu, Zhipeng
Zhou, Hongmei
Ni, Yunjian
Wu, Cheng
Zhang, Caijun
Ling, Xiaoyan
Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis
title Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis
title_full Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis
title_fullStr Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis
title_full_unstemmed Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis
title_short Can dexmedetomidine reduce atrial fibrillation after cardiac surgery? A systematic review and meta-analysis
title_sort can dexmedetomidine reduce atrial fibrillation after cardiac surgery? a systematic review and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856293/
https://www.ncbi.nlm.nih.gov/pubmed/29559768
http://dx.doi.org/10.2147/DDDT.S153834
work_keys_str_mv AT zhuzhipeng candexmedetomidinereduceatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT zhouhongmei candexmedetomidinereduceatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT niyunjian candexmedetomidinereduceatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT wucheng candexmedetomidinereduceatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT zhangcaijun candexmedetomidinereduceatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis
AT lingxiaoyan candexmedetomidinereduceatrialfibrillationaftercardiacsurgeryasystematicreviewandmetaanalysis